Healthcare [ 5/11 ] | Biotechnology [ 54/112 ]
CA | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jun 21, 22 | -0.04 Increased by +92.73% | -0.13 Increased by +532.54% |
| Feb 14, 22 | -0.11 Decreased by -105.67% | -0.08 Decreased by -468.75% |
| Feb 9, 21 | -0.16 Increased by +85.71% | -0.41 Increased by +148.72% |
| Nov 16, 20 | -0.10 Increased by +96.32% | -0.56 Increased by +146.68% |
| Aug 13, 20 | -0.55 Increased by +54.17% | -0.61 Increased by +16.12% |
| Jun 29, 20 | 1.94 Increased by +210.23% | -0.92 Increased by +337.90% |
| Feb 14, 20 | -1.12 Decreased by -100.00% | -1.03 Decreased by -8.48% |
| Nov 13, 19 | -2.72 Increased by +45.16% | -0.92 Decreased by -212.67% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 22 | 0.00 Decreased by N/A% | -3.89 M Decreased by -27.84% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -4.93 M Decreased by -188.92% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 32.00 K Increased by +N/A% | -4.52 M Decreased by -53.25% | Decreased by -14.14 K% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by -100.00% | -4.02 M Increased by +57.26% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by -100.00% | -3.04 M Increased by +31.46% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 21 | 0.00 Decreased by N/A% | 5.54 M Increased by +158.05% | Increased by +N/A% Decreased by N/A% |
| Jun 30, 21 | 0.00 Decreased by N/A% | -2.95 M Increased by +43.35% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 21 | 115.00 K Increased by +N/A% | -9.40 M Decreased by -124.65% | Decreased by -8.18 K% Decreased by N/A% |
Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada.